MARATTO

article · Benha Journal of Applied Sciences

The CHA2DS2-VASc risk score in patients with Non-ST Elevation myocardial infarction to predict total occlusion in infarct-related arteries

Abstract

Patients with non-ST elevation myocardial infarction (NSTEMI) had a better chance of survival fewer ischemic sequelae after undergoing percutaneous coronary intervention (PCI). Patients undergoing percutaneous coronary intervention (PCI) are susceptible to contrast-induced nephropathy (CIN), which poses serious risks such as kidney failure, an upsurge in cardiovascular events, an extended duration of hospitalization, or even mortality. A low beginning estimated glomerular filtration rate (eGFR), poor contrast volume, or reduced blood volume overall are among the several potential causes of chronic interstitial pneumonia (CIN). It highlights the need of identifying individuals who are at risk of CIN during PCI operations. The original intent of the CHA2DS2-VASC score was to categorize patients' risk of stroke due to atrial fibrillation (AF). Older individuals, those with hypertension (HT), diabetes mellitus (DM), heart failure, or who are female are more likely to have poor cardiovascular disease outcomes when using the CHA2DS2-VASC score. The CHA2DS2-VASC score may also be helpful in populations who do not have AF, according to recent studies. Our goal in doing this evaluation is to determine how well CHA2DS2 VASC scores predict complete blockage in infarct-related arteries in patients who have had a non-ST elevation myocardial infarction.

Research topics

  • Coronary Interventions and Diagnostics
  • Cardiac Imaging and Diagnostics
  • Acute Myocardial Infarction Research

Sustainable Development Goals

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

DOI: 10.21608/bjas.2024.310966.1470

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.